You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A chimeric protein for the selective expansion of regulatory T cells
SBC: SAHANE BIOTECH INC Topic: NIAIDDESCRIPTION provided by applicant Type diabetes T D is a chronic disease caused by the autoimmune destruction of the insulin producing beta cells in the pancreas Current treatment options for T D are severely limited All patients diagnosed with T DM are placed on life long insulin therapy and the current standard of care for adult patients with T DM is intensive diabetes therapy to avoid ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Aminomethyl benzamides as novel anti Ebola agents
SBC: Chicago Biosolutions, Inc. Topic: NIAIDEbola EBOV and Marburg MARV viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral infection and pathogenes ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Aminopiperidines as novel anti influenza agents
SBC: Chicago Biosolutions, Inc. Topic: NIAIDInfluenza A viruses belong to the orthomyxoviridae family with a negative sense segmented RNA genome which can cause seasonal or pandemic flu with high morbidity and significant mortality Vaccination is the most prevalent prophylactic means for controlling influenza infections However an effective vaccine usually takes at least months to develop for the circulating strains Furthermore vac ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A mobile app to reduce treatment-related financial burden for cancer patients
SBC: Vivor, Llc Topic: NCIThere is a fundamental knowledge gap in how to immediately reduce cancer patientsandapos treatment related financial burden Cancer patients pay more out of pocket for their care than those with other chronic illnesses Half of all elderly cancer patients have high treatment related out of pocket financial burden This financial burden has well defined harmful effects even among insured cancer pa ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Antiatherogenic Properties of tert-Butylhydroquinone
SBC: BIOINVENTIONS, LLC Topic: N/ADESCRIPTION (provided by applicant): Atherosclerosis is the underlying cause of most cardiovascular disease and considerable evidence supports the role of hypercholesterolemia as a risk factor for this disease. In preliminary work, we found that tertiary-butyl hydroquinone (TBHQ), at a dose lower than approved for human use, was effective in reducing plasma levels of both total cholesterol and tri ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
An Ultra filtrate perfusion bio artificial pancreas for high-density islet replacement without immunosuppression
SBC: Norfolk Medical Products, INC. Topic: NIDDKDESCRIPTION provided by applicant The Cell SafeTM is a fundamentally new approach in replacement of dysfunctional insulin producing cells in patients with diabetes by transplantation of new islets in a three dimensional scaffold embedded in a highly compatible bioengineered perfusion system that continuously supplies tissue fluid blood ultrafiltrate so that the cells ae protected from immun ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A simple and effective diagnostic test for gastrointestinal bleeding to improve patient outcomes
SBC: CUMBERLAND PHARMACEUTICALS, INC. Topic: 300DESCRIPTION provided by applicant Problem Lower gastrointestinal bleeding is a significant medical problem in the United States accounting for more than hospital admissions and tens of billions of dollars of healthcare spending annually It is common for bleeding from a single site to stop and restart multiple times The three modalities now used to diagnose and locate gastrointestina ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Automated, portable, concurrent, WMD detection system
SBC: Concurrent Analytical, Inc. Topic: N/ADESCRIPTION (provided by applicant): The overall goal of this project is the development of a fully automated, wireless ethernet capable, near realtime, field deployable immunoassay-based analysis system for the concurrent, ultra low-level detection of biowarfare agents in air or water by using innovations in surface enhanced Raman scattering (SERS) and related supporting materials and hardware. A ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Caduceus Quest: A serious STEM game to promote reproductive health and STEM and health career interest
SBC: RESILIENT GAMES STUDIO, LLC Topic: ODDESCRIPTION provided by applicant The proposed Phase I STTR project will develop and test a serious game Caduceus Quest to engage youth in STEM learning facilitate reductions in sexual and reproductive health risk behaviors and promote asset development toward holistic long term well being Caduceus Quest will be a multi platform theory based role playing game in which players build up t ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Cardiac Interactions of New Adriamycin Analogs and Taxol
SBC: GEM Pharmaceuticals Topic: N/ADESCRIPTION (provided by applicant): Paclitaxel (Taxol) and doxorubicin (DOX, Adriamycin) are chemotherapeutic drugs used in treatment of metastatic breast cancer. When used individually, they produce a 30-40 percent response rate. When combined, using high doses of DOX (450-550 mg/m2), the response rate is increased to 85-95 percent. This represents a significant improvement in tumor responsivene ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health